Patents Assigned to Universite de Montreal
  • Publication number: 20240239801
    Abstract: Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder is associated with a RAF gene mutation and/or a RAS gene mutation.
    Type: Application
    Filed: April 19, 2022
    Publication date: July 18, 2024
    Applicant: Université de Montréal
    Inventors: Pierre Louis BEAULIEU, Eric BEAULIEU, Sasmita TRIPATHY, Yannick ROSE, Michael DORE
  • Patent number: 12037324
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: July 16, 2024
    Assignees: Bristol-Myers Squibb Company, Université de Montréal
    Inventors: Eldon Scott Priestley, Samuel Kaye Reznik, Edward H. Ruediger, James R. Gillard, Oz Scott Halpern, Wen Jiang, Jeremy Richter, Rejean Ruel, Sasmita Tripathy, Wu Yang, Xiaojun Zhang
  • Patent number: 12038628
    Abstract: A method for determining an optical system intended to equip a person on the basis of the adaptability of the person to a visual and/or proprioceptive modification of his environment, the method including a person visual behaviour parameter providing, during which a person visual behaviour parameter indicative of the visual behaviour of the person relative to a given state of the environment is provided; a reference value providing, during which a first value of the person visual behaviour parameter corresponding to a reference state of the environment is provided; a visual and/or proprioceptive modification providing, during which a visual and/or proprioceptive modification of the reference state of the environment is provided so as to define a modified state of the environment; and determining, during which an optical parameter of the optical system is determined based on the first value of the person visual behaviour parameter and on a second value of the person visual behaviour parameter associated with t
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: July 16, 2024
    Assignees: Essilor International, Universite de Montreal
    Inventors: Guillaume Giraudet, Jocelyn Faubert, Rafael Doti, Eduardo Lugo
  • Patent number: 12011460
    Abstract: It is provided a method of expanding dendritic (DC) cells and/or natural killer (NK) cells in vivo in a patient comprising the steps of producing a graft of stem and progenitor cells cultured with UM171 or analogues therefrom and expanded before being administered to the patient. The expansion or increase in dendritic (DC) cells and/or natural killer (NK) cells population in the patient results in an increase immune response reducing transplant related mortality (TRM), severe graft-versus-host disease (GVHD), relapse, and/or severe viral infections.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: June 18, 2024
    Assignee: UNIVERSITE DE MONTREAL
    Inventors: Guy Sauvageau, Sandra Cohen, Jean Roy, Silvy Lachance, Jean-Sébastien Delisle, Jalila Chagraoui
  • Publication number: 20230338429
    Abstract: The invention relates to compounds as described herein and pharmaceutical compositions containing them. Also, the invention relates to methods for expanding stem cells and/or progenitor cells and methods for treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease.
    Type: Application
    Filed: May 19, 2023
    Publication date: October 26, 2023
    Applicant: Universite De Montreal
    Inventors: Bruno SIMONEAU, Yves CHANTIGNY, Jonathan YEH, Guy SAUVAGEAU, Anne MARINIER
  • Patent number: 11760754
    Abstract: Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: September 19, 2023
    Assignee: UNIVERSITÉ DE MONTRÉAL
    Inventors: Yves Gareau, Stéphane Gingras, Yves Chantigny, Gaoqiang Yang, Guy Sauvageau, Irène Baccelli, Anne Marinier
  • Publication number: 20230287070
    Abstract: Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) shared by a large proportion of AML cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of leukemia such as AML is also described.
    Type: Application
    Filed: March 15, 2021
    Publication date: September 14, 2023
    Applicant: UNIVERSITE DE MONTREAL
    Inventors: Claude Perreault, Pierre Thibault, Sebastien Lemieux, Gregory Ehx, Marie-Pierre Hardy
  • Patent number: 11725187
    Abstract: It is provided a method of expanding ex vivo hematopoietic stem cells (HSC), the method comprising selecting a population of Endothelial Protein C Receptor (EPCR)+ HSC, culturing the selected HSC thereby expanding said EPCR+ HSC and the use of the expanded EPCR+ HSC for stem cells transplantation.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: August 15, 2023
    Assignee: UNIVERSITE DE MONTREAL
    Inventors: Guy Sauvageau, Iman Fares, Jalila Chagraoui
  • Patent number: 11702450
    Abstract: T cells, notably CD8 T cells, are known to be essential players in tumor eradication as the presence of tumor-infiltrating lymphocytes (TILS) in several cancers positively correlates with a good prognosis. To eliminate tumor cells, CD8 T cells recognize tumor antigens, which are MHC I-associated peptides present at the surface of tumor cells, with no or very low expression on normal cells. Described herein a proteogenomic approach using RNA-sequencing data from cancer and normal-matched mTEChi samples in order to identify non-tolerogenic tumor-specific antigens derived from (i) coding and non-coding regions of the genome, (ii) non-synonymous single-base mutations or short insertion/deletions and more complex rearrangements as well as (iii) endogenous retroelements, which works regardless of the sample's mutational load or complexity.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: July 18, 2023
    Assignee: UNIVERSITÉ DE MONTRÉAL
    Inventors: Céline Laumont, Pierre Thibault, Sébastien Lemieux, Claude Perreault
  • Patent number: 11696928
    Abstract: The invention relates to compounds as described herein and pharmaceutical compositions containing them. Also, the invention relates to methods for expanding stem cells and/or progenitor cells and methods for treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: July 11, 2023
    Assignee: UNIVERSITE DE MONTREAL
    Inventors: Bruno Simoneau, Yves Chantigny, Jonathan Yeh, Guy Sauvageau, Anne Marinier
  • Publication number: 20230165812
    Abstract: The present disclosure provides methods of treating cancer by silencing tumor-innervating sensory neurons. The methods include treating cancer by genetic ablation of ion channels (e.g., TRPV1 or NaV1.8), local pharmacological silencing or blockade of neuropeptide release from tumor-innervating nociceptor (e.g., with QX-314 and BoNT/a), as well as the antagonism of the CGRP receptor RAMP1 (e.g., with BIBN 4096).
    Type: Application
    Filed: February 26, 2021
    Publication date: June 1, 2023
    Applicants: President and Fellows of Harvard College, Université de Montréal, Children's Medical Center Corporation
    Inventors: Clifford J. Woolf, Sebastien Talbot, Bruce P. Bean
  • Publication number: 20230158132
    Abstract: Acute lymphoblastic leukemia (ALL) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) specifically expressed by ALL cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells, antibodies and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, antibodies, cells and vaccines for the treatment of leukemia such as ALL is also described.
    Type: Application
    Filed: April 9, 2021
    Publication date: May 25, 2023
    Applicant: UNIVERSITE DE MONTREAL
    Inventors: Claude Perreault, Pierre Thibault, Marie-Pierre Hardy
  • Publication number: 20230122855
    Abstract: Small molecules comprised of azacyclic constrained sphingolipid-like compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
    Type: Application
    Filed: October 13, 2022
    Publication date: April 20, 2023
    Applicants: The Regents of the University of California, The Université de Montréal
    Inventors: Aimee L. Edinger, Stephen Hanessian
  • Publication number: 20230076854
    Abstract: A method for determining an optical system intended to equip a person on the basis of the adaptability of the person to a visual and/or proprioceptive modification of his environment, the method including a person visual behaviour parameter providing, during which a person visual behaviour parameter indicative of the visual behaviour of the person relative to a given state of the environment is provided; a reference value providing, during which a first value of the person visual behaviour parameter corresponding to a reference state of the environment is provided; a visual and/or proprioceptive modification providing, during which a visual and/or proprioceptive modification of the reference state of the environment is provided so as to define a modified state of the environment; and determining, during which an optical parameter of the optical system is determined based on the first value of the person visual behaviour parameter and on a second value of the person visual behaviour parameter associated with t
    Type: Application
    Filed: November 9, 2022
    Publication date: March 9, 2023
    Applicants: Essilor International, Universite de Montreal
    Inventors: Guillaume GIRAUDET, Jocelyn FAUBERT, Rafael DOTI, Eduardo LUGO
  • Publication number: 20230045357
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.
    Type: Application
    Filed: July 11, 2022
    Publication date: February 9, 2023
    Applicants: Université de Montréal, Bristol-Myers Squibb Company
    Inventors: Eldon Scott PRIESTLEY, Samuel Kaye REZNIK, Edward H. RUEDIGER, James R. GILLARD, Oz Scott HALPERN, Wen JIANG, Jeremy RICHTER, Rejean RUEL, Sasmita TRIPATHY, Wu YANG, Xiaojun ZHANG
  • Patent number: 11500224
    Abstract: A method for determining an optical system intended to equip a person on the basis of the adaptability of the person to a visual and/or proprioceptive modification of his environment, the method.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: November 15, 2022
    Assignees: Essilor International, Universite de Montreal
    Inventors: Guillaume Giraudet, Jocelyn Faubert, Rafael Doti, Eduardo Lugo
  • Patent number: 11493782
    Abstract: There is described a medical device for management of the axial length growth of an eye of a subject. The device comprises a central region having a first power, a transition region surrounding the central region, and a peripheral region surrounding the transition region and having a second power. The transition region has a width at most equal to 1.5 mm. The second power is chosen based on the first power to achieve a target net power, the target net power being the addition of the first power and the second power. The surface area of the central and peripheral regions is chosen as a function of the surface area of the pupil of the eye. Furthermore, the curve of power within the transition region is steep between the first power and the second power so that the transition region generates no optically usable power.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: November 8, 2022
    Assignee: Université de Montréal et al.
    Inventors: Patrick Simard, Jean Blanchard, Langis Michaud, Remy Marcotte-Collard
  • Patent number: 11479530
    Abstract: Small molecules comprised of azacyclic constrained sphingolipid-like compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: October 25, 2022
    Assignees: The Regents of the University of California, The Université de Montréal
    Inventors: Aimee L. Edinger, Stephen Hanessian
  • Publication number: 20220284303
    Abstract: A system simulating a decisional process in a mammal brain about characteristics of motions related to body gestures of a visually observed body through a simulated visual path is provided. The system includes an interface toward simulated neuronal structures, the interface at least converting luminous information of the observed body to an optic flow data stream conveying information related to the visually observed body and that can be processed in the simulated neuronal structures, the system being a feed-forward system and comprising hierarchically from the visual observation to the decision: the simulated visual path and its interface, a simulated local motion direction detection neuronal structure for the detection of motion directions with receptive fields, a simulated opponent motions detection neuronal structure, a simulated complex patterns detection neuronal structure, and a simulated motion pattern detection neuronal structure.
    Type: Application
    Filed: August 3, 2020
    Publication date: September 8, 2022
    Applicants: UNIVERSITE DE MONTREAL, Essilor International
    Inventors: Jocelyn FAUBERT, Khashayar MISAGHIAN, Eduardo LUGO, Delphine TRANVOUEZ-BERNARDIN
  • Publication number: 20220266017
    Abstract: A method for modulating a movement of a body part comprising: acquiring movement event data relating to the body part during a movement event, the movement event data including: a movement event parameter requiring modulation, a trigger value representative of a first time point in the movement event, and a target value representative of desired movement at a second, later, time point in the movement event; acquiring in real-time current movement data associated with a current movement event of the body part, the current movement data including current values of the movement event parameter; analyzing the current movement data to determine presence of the trigger value in the current movement event; and in response to identification of the trigger value in the current movement data, causing a brain stimulation assembly to apply a predetermined modulation signal to a brain motor region of the subject to cause the modulation of the body part towards the target value at the second time point in the current movem
    Type: Application
    Filed: July 30, 2020
    Publication date: August 25, 2022
    Applicant: UNIVERSITÉ DE MONTRÉAL
    Inventors: Marco Bonizzato, Marina Martinez